Sort
10,766 grants matching “checkpoint inhibitor”
Genome-wide networks that modulate the T-lineage cell fate
$387,500Cornelis Murre · Research Inst Of Fox Chase Can Ctr · P01 · FY2017 · AI
Stinging the Glioma Immune Landscape
$387,468Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · NS
Regulation of Chromosome Segregation in Human Cells
$387,432Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2012 · GM
Regulation of Chromosome Segregation in Human Cells
$387,432Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2011 · GM
Project 1 Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN
$387,285Michael Davies · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA
DNA damaging therapy and immune response in small cell lung cancer subtypes
$387,250Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
DNA damaging therapy and immune response in small cell lung cancer subtypes
$387,250Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Advanced development and validation of genome-scale molecular diagnostics for microsatelliteinstability using targeted molecular counting methods
$387,195Stephen J Salipante · University Of Washington · R33 · FY2020 · CA
Genome-wide networks that modulate the T-lineage cell fate
$387,159Cornelis Murre · Research Inst Of Fox Chase Can Ctr · P01 · FY2018 · AI
Vulnerabilities of MMR-deficient glioblastoma
$387,027Benjamin W. Purow · University Of Virginia · R01 · FY2024 · NS
Novel immunotherapeutic potential of DGKalpha inhibition for glioblastoma
$387,027Benjamin W. Purow · University Of Virginia · R01 · FY2024 · NS
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
$386,860Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · CA
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
$386,846Brent Allen Hanks · Duke University · R01 · FY2022 · CA
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
$386,825Shweta Joshi · University Of California, San Diego · R01 · FY2024 · NS
Research Project Cervical Cancer
$386,806Julie Kristina Schwarz · Washington University · U54 · FY2023 · CA
Epigenetic Therapy for Thoracic Malignanceis
$386,745David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Advanced development and validation of genome-scale molecular diagnostics for microsatelliteinstability using targeted molecular counting methods
$386,677Stephen J Salipante · University Of Washington · R33 · FY2018 · CA
Development of CA-IL-12 for Triple Negative Breast Cancer
$386,586Richard L. Klemke · Cytonus Therapeutics, Inc. · R41 · FY2020 · CA
Proj 2 - Exploiting Therapeutic Vulnerabilities
$386,498William A Weiss · Children'S Hosp Of Philadelphia · P01 · FY2020 · CA
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$386,442Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2022 · CA
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices
$386,374Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2020 · CA
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices
$386,374Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2021 · CA
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices
$386,374Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2022 · CA
Vimentin-mediated regulation of the inflammasome in acute lung injury
$386,250Karen M Ridge · Northwestern University At Chicago · R01 · FY2018 · HL
PPARy, TLR Signaling and Atherosclerosis
$386,250Christopher K Glass · University Of California, San Diego · P01 · FY2009 · HL